Search - tctmd.com

Displaying 1 - 20 of 173

Sort: Relevancy | Date

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

News Conference News AHA 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

November 17, 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials

News Conference News AHA 2025

Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials

Yael L. Maxwell

November 13, 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

News Conference News AHA 2025

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

November 10, 2025

DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients

News Conference News AHA 2025

DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients

Michael O'Riordan

November 09, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

ICD No Help for High-Risk, Post-MI Patients With Moderately Reduced EF

News Conference News ESC 2025

ICD No Help for High-Risk, Post-MI Patients With Moderately Reduced EF

September 02, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

MitraClip Safe and Effective in Non-COAPT-Like Patients: EXPANDed

News Conference News NY Valves 2025

MitraClip Safe and Effective in Non-COAPT-Like Patients: EXPANDed

Yael L. Maxwell

July 03, 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

News Conference News HRS 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

April 29, 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

News Conference News EHRA 2025

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

March 31, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.